Evidence map›Paper›PMID 35356603›Full record

ArticleOcular oncology and pathology2022

Combination of Brachytherapy and Intravitreal Chemotherapy in the Treatment of Retinoblastoma with Vitreous Seeding.

Sabrina Schlüter, Norbert Bornfeld, Elbrus Valiyev, Dirk Flühs, Martin Stuschke, Nikolaos E Bechrakis, Tobias Kiefer, Petra Ketteler, Sophia Göricke, Eva M Biewald

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ocular oncology and pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Innovations in brachytherapy.Taiwan journal of ophthalmology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sabrina SchlüterDepartment of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Norbert BornfeldDepartment of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Elbrus ValiyevDepartment of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Dirk FlühsDepartment of Radiotherapy, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Martin StuschkeDepartment of Radiotherapy, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Nikolaos E BechrakisDepartment of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Tobias KieferDepartment of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Petra KettelerDepartment of Paediatric Haematology/Oncology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Sophia GörickeDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Eva M BiewaldDepartment of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
University of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The aim of this study was to report the efficacy of combined intravitreal chemotherapy (IVC) and ruthenium-106 brachytherapy in retinoblastoma, either as first-line or second-line treatment, following systemic chemoreduction or intra-arterial chemotherapy. Methods: Retrospective data of 18 eyes from 18 patients treated with IVC and brachytherapy from August 2014 to December 2019 were collected. Results: The method described was our first-line therapy in 6 patients, whereas it was used as second-line treatment after chemoreduction in the remaining 12 patients. The eyes showed the following classification at initial presentation: 2 group B eyes, 3 group C eyes, and 13 group D eyes. The mean follow-up was 19.5 months (range 2-53 months). The mean patient age at brachytherapy was 34.0 months (range 15-83 months). The median prescribed dose at the tumour base and apex was 574.5 ± 306.7 Gy and 88.5 ± 12.2 Gy, respectively. The ocular retention rate was 66.7%. Six eyes had to be enucleated due to uncontrollable subretinal and recurrent vitreous seeding, tumour relapse, recurrence of a solid tumour elsewhere in the eye, and persistent vitreous bleeding with loss of tumour control. The mean number of intravitreal injections of melphalan was 5.0. Two patients received a simultaneous injection of topotecan for insufficient therapeutic response. With regard to radiogenic complications, we could observe temporary retinal and vitreous bleeding (27.8%), serous retinal detachment (44.4%), and radiogenic maculopathy and retinopathy (11.1%). None of the children showed metastatic disease during follow-up. Conclusion: Ruthenium-106 plaque therapy in combination with IVC is an effective local therapy with good tumour control rates even in advanced eyes. Overall, the analysed therapeutic approach shows an acceptable side-effect profile, especially when considering that external-beam radiation therapy and systemic polychemotherapy or at least the number of cycles needed, with their increased incidence of adverse events, can thus be avoided.

Indexed as

ChemoreductionExternal-beam radiation therapyIntravitreal therapyOptic neuropathyRadiation maculopathy

Identifiers

PMID35356603
PMCPMC8914268
OpenAlexW3217212630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.